



Prior Attorney Docket No.: CPMC-01000US1

Attorney Docket No: CPMC-033/01US

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on JUNE 8, 2004.

By:

Hanna Hacham 6-404

Hanna Hacham

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lee et al.

Serial No.: 10/690,880

Examiner: not yet assigned

Confirmation No.: 8369

Art Unit: 1645

Filed: October 22, 2003

For: **BIOMARKER PANEL FOR COLORECTAL CANCER**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08A for the above-identified patent application.

- ☒ In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.
- ☐ In accordance with 37 C.F.R. §1.97(c), also enclosed is:
- ☐ the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p); or
- ☐ a statement as specified in 37 C.F.R. §1.97(e).
- ☐ In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. §1.97(e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.
- ☐ Check No. ___ in the amount of \$___ for the total fee is attached.
- ☐ A return receipt postcard is also enclosed.
- ☐ Please charge \$___ to Deposit Account No. 03-3117 for the total fee. This paper is being submitted in duplicate.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 03-3117.


Dated: 6/1/04

Cooley Godward LLP
ATTN: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000 Fax: (650) 857-0663
TMM/hh

Respectfully submitted,
COOLEY GODWARD LLP

By:

Tom M. Moran
Tom M. Moran
Reg. No. 26,314



Prior Attorney Docket No.: CPMC-01000US1

Attorney Docket No: CPMC-033/01US

PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on JUNE 4, 2004.

By: Hanna Hacham 6-4-04

Hanna Hacham

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Lee et al.

Serial No.: 10/690,880

Examiner: not yet assigned

Confirmation No.: 8369

Art Unit: 1645

Filed: October 22, 2003

For: **BIOMARKER PANEL FOR COLORECTAL CANCER**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b)**

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, a copy of each document cited in the attached Form PTO/SB/08 is enclosed.
- ☐ No copies of the publications listed on the attached Form PTO/SB/08A are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No. to which the above-identified application claims priority under 35 U.S.C. §120.
- ☐ No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO/SB/08A are being provided pursuant to 37 C.F.R. §1.98 because this application was filed after June 30, 2003.
- ☐ Publication(s) ___ listed on the attached Form PTO/SB/08A were cited in a foreign search or examination report corresponding to ___ application serial no. and mailed on ___.

- ☐ Enclosed is a copy of a non-English publication(s) _____. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- ☐ Enclosed is a copy of a non-English publication(s) _____. English language publication ____ (copy enclosed) claims priority from this non-English publication.
- ☐ Enclosed is an explanation of non-English publication(s) ____ for which an English translation is not available.
- ☐ Enclosed is an English translation of non-English publication(s) ____ cited in the attached Form PTO/SB/08A.
- ☐ Enclosed is a copy of pending patent Application Serial No. _____.

This Information Disclosure Statement is filed within any one of the following time periods:

- ☐ within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☐ within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;
- ☒ before the mailing date of a first office action on the merits; or
- ☐ before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.


It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08A to the undersigned.

Dated: 6/1/04

Cooley Godward LLP
ATTN: Patent Group
Five Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306-2155
Tel: (650) 843-5000 Fax: (650) 857-0663
TMM/hh

Respectfully submitted,
COOLEY GODWARD LLP

By:


Tom M. Moran
Reg. No. 26,314



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/690,880
				Filing Date	October 22, 2003
				First Named Inventor	Lee
				Group Art Unit	1645
				Examiner Name	unassigned
Sheet	1	of	3	Attorney Docket Number	CPMC-033/01US


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ¹ (if known)		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	C1	Bamba, H., et al. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int J Cancer, 83: 470-475, 1999.		
	C2	Bianchi, et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res, 54: 861-866, 1994.		
	C3	Buckhaults, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res., 61: 6996-7001, 2001.		
	C4	Coussens and Werb, Inflammation and cancer. Nature, 420: 860-867, 2002.		
	C5	Denhardt, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest, 107: 1055-1061., 2001.		
	C6	Eberhart, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 1183-1188, 1994.		
	C7	Giordano, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol, 159: 1231-1238, 2001.		



C8	Guda, et al. Multistage gene expression profiling in a differentially susceptible mouse colon cancer model. <i>Cancer Lett</i> , 191: 17-25, 2003.	
C9	Gupta, et al. Aspirin, NSAIDS, and colon cancer prevention: mechanisms? <i>Gastroenterology</i> , 114: 1095-1098, 1998.	
C10	He, et al. Identification of c-MYC as a target of the APC pathway. <i>Science</i> , 281: 1509-1512., 1998.	
C11	Hegde, et al. Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. <i>Cancer Res</i> , 61: 7792-7797, 2001.	
C12	Hull, et al. Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice. <i>Br J Cancer</i> , 79: 1399-1405, 1999.	
C13	Ieda, et al. Immunohistochemical analysis of p53 and ras p21 expression in colorectal adenomas and early carcinomas. <i>Surg Today</i> , 26: 230-235, 1996.	
C14	Inaba, et al. Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. <i>Proc Natl Acad Sci U S A</i> , 100: 2736-2741, 2003.	
C15	Kitahara, et al. Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. <i>Cancer Res</i> , 61: 3544-3549, 2001.	
C16	Koh, et al. C. Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. <i>J Clin Invest</i> , 106: 533-539., 2000.	
C17	Li, et al. Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. <i>Clin Cancer Res</i> , 7: 3298-3304, 2001.	
C18	Lin, et al. Identification of AF17 as a downstream gene of the beta-catenin/T-cell factor pathway and its involvement in colorectal carcinogenesis. <i>Cancer Res</i> , 61: 6345-6349, 2001.	
C19	Loukinova, et al. Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. <i>Oncogene</i> , 19: 3477-3486, 2000.	
C20	Marnett and DuBois, COX-2: a target for colon cancer prevention. <i>Annu Rev Pharmacol Toxicol</i> , 42: 55-80, 2002.	
C21	Muller-Decker, et al. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. <i>Proc Natl Acad Sci U S A</i> , 99: 12483-12488, 2002.	
C22	Muro, et al. Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data. <i>Genome Biol</i> , 4: R21, 2003.	
C23	Notterman, et al. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. <i>Cancer Res</i> , 61: 3124-3130., 2001.	
C24	Oshima, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). <i>Cell</i> , 87: 803-809., 1996.	



C25	Paulsen, et al. Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon. Cancer Res, 61: 50105015., 2001.	
C26	Roy, et al. Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal antiinflammatory drug nabumetone. Int J Cancer, 92: 609-615, 2001.	
C27	Sherr, The Pezcoller lecture: cancer cell cycles revisited. Cancer Res, 60: 3689-3695., 2000.	
C28	Siu, et al. The identification of monoclonality in human aberrant crypt foci. Cancer Res, 59: 63-66., 1999.	
C29	Tureci, et al. Computational dissection of tissue contamination for identification of colon cancer-specific expression profiles. Faseb J, 17: 376-385, 2003.	
C30	Williams, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res, 9: 931-946, 2003.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.